To go back to the main page, click here
| S.No | Drug Name | Biological Name | Developer | Current Development Phase | Additional Information | Start Date | Completion Date | Source |
| 11 | - | carcinoembryonic antigen RNA-pulsed DC cancer vaccine | Duke University, National Cancer Institute (NCI) | I | Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment. | 2000 | 2009 | Source |
| 12 | - | carcinoembryonic antigen RNA-pulsed DC cancer vaccine | Duke University, National Cancer Institute (NCI) | I/II | Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer. | 1999 | 2009 | Source |
| 13 | - | QS21, ras peptide cancer vaccine | Fox Chase Cancer Center, National Cancer Institute (NCI) | I | Phase I trial to study the effectiveness of vaccine therapy plus QS21 in treating patients who have advanced pancreatic or colorectal cancer. | - | - | Source |
| 14 | GI-4000 | - | GlobeImmune | II | The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time | 2010 | 2013 | Source |
| 15 | - | Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated | Hadassah Medical Organization | I/II | This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer | - | - | Source |
| 16 | Endoxana, Leukine, IMA910, Aldara | - | Immatics Biotechnologies GmbH | I/II | This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients with advanced CRC to warrant further development | 2008 | 2012 | Source |
| 17 | - | PSMA/PRAME | MannKind Corporation | I | Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. |
2007 | 2009 | Source |
| 18 | MEDI-547 | - | MedImmune/Anza | I | Terminated. Purpose was: To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory solid tumors |
2009 | 2010 | Source |
| 19 | - | V930 /V932 | Merck | I | Completed. Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens |
2007 | 2009 | Source |
| 20 | - | V934/V935 | Merck | I | Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors. |
2008 | 2011 | Source |
| 21 | Detox-B adjuvant, ras peptide cancer vaccine | - | National Cancer Institute (NCI) | I | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. | 1995 | Ongoing | Source |
| 22 | Detox-B adjuvant, ras peptide cancer vaccine | - | National Cancer Institute (NCI) | I | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. | 1995 | Ongoing | Source |
| 23 | - | Interleukin-2 | National Cancer Institute (NCI) | II | Phase II trial to study the effectiveness of a vaccine made with the patients’ white blood cells mixed with tumor proteins in treating patients who have advanced cancer. | - | - | - |
| 24 | - | Aldesleukin, ras peptide cancer vaccine | National Cancer Institute (NCI) | I/II | Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer. | 1999 | Ongoing | Source |
| 25 | Detox-B adjuvant, ras peptide cancer vaccine | - | National Cancer Institute (NCI) | I | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. | 1995 | Ongoing | Source |
| 26 | Detox-B adjuvant, ras peptide cancer vaccine | - | National Cancer Institute (NCI) | I | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. | 1995 | Ongoing | Source |
| 27 | - | ONT-10 | Oncothyreon | Preclinical | - | - | - | - |
| 28 | Interferon-alpha | Trovax | Oxford BioMedica | II | Study has been completed | 2006 | 2008 | Source |
| 29 | - | AdhTAP | TapImmune | Preclinical | - | - | - | - |
| 30 | - | OncoVAX autologous vaccine |
Vaccinogen | III | Available in Netherlands/Switzerland Possible U.S. and E.U. approvals in 2014 | - | - | - |
| 31 | - | CEA DNA Cancer Vaccine |
Vical/Merck | I | The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. | 2007 | 2009 | - |
To go back to the main page, click here